Olesoxime Failed to Benefit SMA Type 2 and 3 Patients, Final Trial Data Show
Dec 07, 2020, 12:00 AM
SMA News Today’s multimedia associate, Price Wooldridge, discusses how olesoxime failed to benefit Spinal Muscular Atrophy (SMA) Type 2 and 3 patients in a final trial.
SMA News Today’s forums moderator, DeAnn Runge discusses recent topics in the SMA News Today forums. A big topic of course is COVID. From dealing with the effects to anticipating the vaccine many discussions revolve around it. In other news Michael Morale’s latest YouTube video has been posted regarding the steps he took to get the latest FDA approved treatment Everysdi. Other conversations in our forums include relieving neck tension, disease progression, switches and favorite assistive technology.
SMA News Today’s forums moderator, DeAnn Runge discusses recent topics in the SMA News Today forums. A big topic of course is COVID. From dealing with the effects to anticipating the vaccine many discussions revolve around it. In other news Michael Morale’s latest YouTube video has been posted regarding the steps he took to get the latest FDA approved treatment Everysdi. Other conversations in our forums include relieving neck tension, disease progression, switches and favorite assistive technology.
================================
To learn more about Evrysdi, please visit http://www.ApprovedForSMA.com
================================
To take part in our ongoing discussions regarding SMA, please visit http://www.smanewstoday.com/forums
================================
For the most up-to-date information regarding SMA, please visit http://www.smanewstoday.com